Progyny Lands 1.3 Million New Covered Lives, Its Biggest Selling Season, And Raises Guidance Midpoint

The fertility-benefits company posted record third-quarter revenue of $341.3 million and net income of $26.3 million, nearly double a year ago.

Share
Progyny Lands 1.3 Million New Covered Lives, Its Biggest Selling Season, And Raises Guidance Midpoint

Progyny, which sells fertility and family-building benefits to employers, signed 1.3 million new covered lives in its latest selling season, its most ever in one season, and raised the midpoint of its 2026 guidance, the company said Wednesday. Third-quarter revenue rose 8.9% to $341.3 million and net income reached $26.3 million, both records.

Profit nearly doubles on lower stock pay

Net income was $26.3 million, or $0.32 per diluted share, against $13.9 million, or $0.15, a year earlier. The company credited higher gross profit and lower stock-based compensation, partly offset by lower interest and other income.

Revenue grew from $313.3 million on more clients and covered lives. Fertility benefit services brought in $223.4 million, up 10.6%, and pharmacy benefit services $117.9 million, up 5.8%. Gross profit rose 15% to $83.7 million, lifting gross margin to 24.5% from 23.2%.

Adjusted EBITDA, a profit measure that is not standard accounting, rose 6.3% to $58.4 million. Its margin slipped to 17.1% from 17.5% as the company made planned investments in platform features.

A record season and near-full retention

The season added more than 85 new clients and renewed the existing base at near 100% retention for 2027, CEO Pete Anevski said. The company had 607 fertility and family-building clients at September 30, up from 553 a year earlier. Average members rose to 7,176,000 from 6,757,000.

Most of the new clients and lives are expected to go live in the first quarter of 2027, with a meaningful number launching mid-year. Once all are live, the company anticipates more than 660 clients covering about 8.3 million lives.

Progyny sells fertility, pregnancy, menopause and related benefits to employers, which offer them to workers and dependents. Anevski said the company's ability to "bend the cost curve" positions it for continued success.

Buybacks and the raised outlook

The company repurchased nearly 3 million shares for $82.7 million in the quarter, and nearly 11 million so far in 2026. About $51 million remains under its $200 million May 2026 authorization. Cash and marketable securities were $195.6 million, down $41.3 million from June 30, with no debt and an undrawn $200 million credit facility.

Full-year revenue is now projected at $1.365 billion to $1.385 billion, and net income at $107.0 million to $110.6 million. Fourth-quarter revenue is guided to $344.7 million to $364.7 million, with net income of $28.5 million to $32.1 million.

The company expects to give 2027 guidance with its year-end results in February.

Progyny plans to give 2027 financial guidance when it reports year-end results in February.

Sources